Business, energy, technology, markets and global industry news from Business News Today

NCCN guidelines

PharmaDeviceNews NCCN guidelines
Pharma & Biotech

ROSELLA trial at ASCO 2026: Corcept’s Lifyorli subgroup data and what it means for platinum-resistant ovarian cancer practice

Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.

Read More
Pharma & Biotech

Gene therapy gains ground in bladder cancer as NCCN strengthens Ferring Pharmaceuticals’ ADSTILADRIN recommendation

ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.

Read More
Merlin CP-GEP becomes first NCCN-endorsed molecular test for early-stage melanoma risk assessment
Medical Devices & Diagnostics

Merlin CP-GEP becomes first NCCN-endorsed molecular test for early-stage melanoma risk assessment

NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.

Read More